维普期刊资源整合服务平台（V6.5）

29篇 您的检索式：作者名="Castel Y"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	lntragastric acid suppres- sion and pharmacokinetics of twice-daily esomeprazole: a ran domized, three-way crossover study 显示文摘	Katz PO Castell DO Chen Y	2004	Aliment Pharmacol Ther2004，20，4：	1
2	The significance of skeletal-related events for the health-related quality of life of patients withmetastatic prostate cancer显示文摘	Weinfurt KP Li Y Castel LD	2005	Ann Oncol2005，16，4：	1
3	A simulation model of wind erosion and sedimen tation as a basis for management of a drift sand area in theNetherlands 显示文摘	Castel I I Y	1988	Earth Surface Processes and Landforms1988，13，6：	1
4	Performance Characteristics of Spiral-Groove and Shrouded Rayleigh Step Profiles for High-Speed Noncontacting Gas Seals显示文摘	H S Cheng V Castell C Y Chow	1969	ASME Journal of Lubrication Technology1969，，1：	1
5	Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole:a randomized,three-way crossover study显示文摘	Katz PO Castell DO Chen Y	2004	Aliment Pharmacol Ther2004，20，：	1
6	The significance of skeletal-rela- ted events for the health-related quality of life of patients with metastatic prostate cancer显示文摘	Weinfurt KP Li Y Castel LD	2005	Ann Oncol2005，16，4：	1
7	Pharmacogenetics implementation in the clinics:information and guidelines for germline variants显示文摘The aim of this work was to supply an overview of the germline Pharmacogenetics that can be already implemented in the oncology clinical practice.An explanation of the three pillars considered necessary for determining which genetic polymorphisms should be used has been provided.These are PharmGKB single nucleotide polymorphism(SNP)-Drug Clinical Annotations with levels of evidence 1 or 2;the genetic information provided in the drug labels by the drug regulatory main agencies(Food and Drug Administration and European Medicines Agency,mainly);and the guidelines elaborated by international expert consortia(mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group).A summary of the relevant SNPs and the recommendations on how to apply their results has also been compiled.	Gladys Olivera Luis Sendra María JoséHerrero Pablo Berlanga Pablo Gargallo Yania Yáñez Andrea Urtasun Jaime Font de Mora Victoria Castel Adela Cañete Salvador FAliño	2019	Cancer Drug Resistance2019，2，1：	1
8	Using SIR-C SAR data and the AMAP model for forest attributes retrieval and 3-D stand simulation显示文摘	Castel T Caraglio Y Beaudoin A	2001	Remote Sens Environ2001，75，：	1
9	The significance of skeletal - related events for the health - related quality of life of patients with metastatic prostate cancer显示文摘	Weinfurt KP Li Y Castel LD	2005	Ann Onco12005，16，4：	1
10	The significance of skeletal-re-lated events for the health-related quality of life of patients with meta- static prostate cancer显示文摘	Weinfurt KP Li Y Castel LD	2005	Ann Oncol2005，16，4：	1
11	Encephalite aigue virale mortelle au cours d'un traitement par le levamisole显示文摘	Mabin D Castel Y Le Fur JM	1978	Presse Med1978，，7：	1
12	Intragastric acid suppression and pharmaeokinetics of twice-daily esomeprazole:a randomized,three-way crossover study 显示文摘	Katz PO Castell DO Chen Y	2004	Aliment Pharmacol Ther2004，20，4：	1
13	Using SIR-C SAR data and the AMAP model for forest attributes retrieval and 3-D stand simulation显示文摘	Castel T Caraglio Y Beaudoin A	2001	Remote Sensing of Environment2001，75，2：	1
14	Hazards for pain severity and pain interference with daily living, with exploration of brief pain inventory cut-points, among women with metastatic breast cancer显示文摘	Castel LD Abernethy AP Li Y	2007	J Pain Symptom Manage2007，34，：	1
15	The impact of skeletal of life of patients with metastatic prostate cancer显示文摘	Weinfurt KP Li Y Castel LD	2002	Ann Oncol2002，13，5：	1
16	The impact of skeletal ot life of patients with metastatic prostate cancer显示文摘	Weinfurt KP Li Y Castel LD	2002	Ann Oncol2002，13，5：	1
17	The significance of skeletal-related events for the health- related quality of life of patients with metastatic prostate cancer 显示文摘	Weinfurt KP Li Y Castel LD	2005	Ann Oncol2005，16，4：	1
18	Intragzstric acid suppression and pharmacokinetics of twice - daily esomeprazole: a randomized, three - way crossover study 显示文摘	Katz PO Castell DO Chen Y	2004	Aliment Pharmacol Ther2004，1520，4：	1
19	Mapping of a target region of allelic loss to a 0.5-cM interval on chromosome 22q13 in human colorectal cancer显示文摘	Castells A Ino Y Louis DN Ramesh V Gusella JF Rustgi AK		0，，：	1
20	Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions 显示文摘	Weinfurt KP Castel LD Li Y	2004	Med Care2004，42，2：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示